Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03538275 · ClinicalTrials.gov registry record
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
A clinical trial, sponsored by Medibio Limited.
- Completed
- Registry status
- 80
- Enrollment target
NCT03538275 is a clinical trial that has completed, run by Medibio Limited. The registered enrollment target is 80 participants.
The verdict
NCT03538275 has completed, sponsored by Medibio Limited.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize autonomic, circadian, and sleep patterns before and during the initial 8 weeks of pharmacologic therapy for moderate-to-severe depression. The study will also explore any differences in these measures between treatment responders and non-responders, and between depression subtypes, including bipolar and unipolar depression. The study will also characterize longitudinal, ambulatory EEG measures throughout the observation period.
Interventions
- OTHER Monitoring test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-03-13 |
| Est. Completion | 2019-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03538275
The ClinicalTrials.gov registry entry for NCT03538275 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medibio Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Monitoring test is the first listed.
NCT03538275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03538275 about?
NCT03538275 is a clinical study titled "Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes". An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize...
What is the current status of trial NCT03538275?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2018-03-13. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03538275?
The interventions under investigation include: Monitoring test (OTHER).
Who is sponsoring clinical trial NCT03538275?
This trial is sponsored by Medibio Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.